A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.

NCT07747090 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG: FXS6837 Capsule
BIOLOGICAL: Eculizumab infusion

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.